If you invest through a European broker, Amundi and Xtrackers are the two issuers you keep bumping into that are not American. Amundi is Europe’s largest home-grown asset manager, and since it swallowed Lyxor it runs the biggest EU-domestic ETF range on the continent. Xtrackers is the ETF arm of DWS, the asset manager that grew out of Deutsche Bank, building index funds for European investors since 2007.
The honest short answer: on headline cost, Amundi’s Prime range is very hard to beat, with core trackers priced around 0.05% and its all-world fund near 0.07%. Xtrackers rarely wins the pure price war, but it counters with a stable line-up, a synthetic heritage that still pays off for US equity exposure, and far fewer surprise fund mergers and ISIN changes. I hold funds from both, and the right pick depends mostly on whether you value the last basis point of fee or a line-up that stays put for a decade.
Amundi and Xtrackers at a glance
Amundi manages roughly €250 billion in ETF assets in 2026, making it the second-largest issuer in Europe behind iShares and the largest that is actually headquartered here. Its modern range is really two ranges stapled together: the legacy Amundi and Lyxor funds, mostly Luxembourg and France domiciled, plus the newer ultra-cheap Prime series that has been grabbing headlines and inflows. I went deeper on how it stacks up against the American giants in my Amundi vs iShares comparison and Amundi vs Vanguard comparison.
Xtrackers sits a tier below on assets, around €200 billion, but it is no niche player. DWS launched the brand as a swap-based (synthetic) house in 2007, converted most core equity funds to physical replication during the 2010s, and today runs one of the widest ranges in Europe. Both are systemically large, well-regulated UCITS issuers, so fund safety in the “will my money vanish” sense is not the deciding factor. The differences live in cost, structure and stability.
Core fund costs: Prime pricing vs Xtrackers TERs
This is where Amundi has changed the European market. The Prime range tracks Solactive indices instead of MSCI or FTSE, which cuts index licensing costs, and Amundi passes that saving on. Prime S&P-style US, European and global developed trackers sit around 0.05% TER, and the Prime All-Country World fund (WEBN) launched near 0.07%. For context, that undercuts most established all-world funds by more than half. I broke down the two Prime world variants in my WEBN vs WEBG comparison.
Xtrackers is competitive rather than cheapest. Its MSCI World core fund has long sat around 0.12% to 0.19% depending on share class, its S&P 500 swap fund is priced aggressively at well under 0.10%, and its emerging markets and bond funds are mid-pack. DWS has cut fees several times in response to the price war, but its strategy is clearly not to win on TER alone.
Two caveats before you decide on price. First, TER is not total cost: tracking difference, spreads and lending revenue all move the real number, and a well-run 0.12% fund can end up cheaper in practice than a sloppy 0.05% one, as I showed in my EUNL vs IUSQ fee analysis. Second, all figures here are 2026-vintage and approximate; both issuers adjust fees, so check the current factsheet before you buy.
Head-to-head comparison table
| Feature | Amundi | Xtrackers (DWS) |
|---|---|---|
| Parent and heritage | Crédit Agricole group, France; absorbed Lyxor in 2022 | DWS, spun out of Deutsche Bank, Germany |
| ETF assets (approx. 2026) | ~€250bn, #2 in Europe | ~€200bn, #3–4 in Europe |
| Cheapest core trackers | Prime range ~0.05%; all-world ~0.07% (Solactive indices) | Core funds ~0.06–0.20%; swap S&P 500 aggressively priced |
| Replication | Mostly physical; some synthetic legacy Lyxor funds | Physical core plus a deliberate, well-maintained synthetic line |
| Main domiciles | Luxembourg and France, newer Irish funds for US equity | Luxembourg and Ireland |
| Fund line-up stability | Weak spot: history of mergers, ISIN changes and domicile moves | Generally stable; changes are rare and well telegraphed |
| Securities lending | Yes, on many physical funds, collateralised | Yes, with a majority of revenue returned to the fund |
| Best suited for | Cost-focused accumulators comfortable with occasional admin | Buy-and-forget investors, synthetic US equity, German savings plans |
Range breadth: who covers more ground
On raw fund count the two are close, and both dwarf Vanguard’s tight European shelf. Amundi’s catalogue is enormous once you include the Lyxor legacy: broad equity, bonds, a deep ESG and climate range, sector funds and some genuinely niche exposures. The catch is that it still shows the seams of the merger, with overlapping funds tracking similar indices at different fees.
Xtrackers’ range feels more deliberately curated. Core equity and bond building blocks, a strong ESG-screened series, single-country funds that few others bother with, and a distinctive synthetic line covering US equity and money-market-style exposures. If you want one issuer to cover a whole portfolio without overlap confusion, I find the Xtrackers shelf easier to work with. For a wider view of how all the big issuers compare on range, see my European ETF providers comparison.
Replication: the synthetic question
Xtrackers began life as a swap house, and although its flagship world and European trackers are physical today, DWS kept synthetic replication where it has a structural edge. The clearest case is US equities: a swap-based UCITS fund can receive the S&P 500 gross return without the 15% dividend withholding tax that even Irish-domiciled physical funds pay, historically worth roughly 0.2% a year. In exchange you accept swap counterparty risk, which UCITS rules cap and issuers over-collateralise in practice.
Amundi also runs synthetic funds, mostly inherited from Lyxor, but its direction of travel has been toward physical. My take: Xtrackers treats synthetic replication as a core competence; Amundi treats it as legacy plumbing. If you want a swap-based S&P 500 fund, Xtrackers is the more natural home; if synthetic structures make you uneasy, both offer physical alternatives for every mainstream index.
Domicile, tax and the Lyxor aftermath
Domicile matters because Luxembourg-domiciled funds pay 30% US withholding tax on dividends inside the fund, while Irish-domiciled funds pay 15% under the US-Ireland treaty. Xtrackers domiciles its physical US and world equity funds in Ireland where it counts, with Luxembourg used for synthetic and European exposures where the treaty advantage is irrelevant. Amundi has historically been Luxembourg and France centred, and has been shifting US-heavy funds to Ireland precisely to capture that treaty benefit.
Here is the uncomfortable part for Amundi. Those domicile moves, plus the post-Lyxor rationalisation, meant a wave of fund mergers, ISIN changes and index switches between roughly 2021 and 2024. In several countries a merger or domicile change counts as a taxable disposal, so buy-and-hold investors were handed capital gains tax bills they never asked for; German investors felt this particularly hard. Forced tax events are a real cost, and Amundi has generated more of them than any other big issuer. Xtrackers’ line-up has been boringly stable by comparison, which is exactly what you want from a fund you plan to hold for twenty years. How a merger is taxed depends on your country’s rules, so verify with your local tax authority or an adviser.
Learning ETFs the slow way?
The free 12-page Starter Kit gets you to a first, sensible portfolio faster: the 7-filter fund shortcut, the 3-question broker matrix, and the 7 costliest beginner mistakes.
Securities lending and revenue sharing
Both issuers lend securities from physical funds to generate extra return. Xtrackers publishes its programme details and returns the majority of gross lending revenue to the fund; Amundi lends across many physical funds on similar collateralised terms, with UCITS collateral rules applying to both. The revenue typically offsets a slice of the TER, so I treat this as a mild positive for both rather than a differentiator. Check a specific fund’s annual report if lending bothers you, and compare candidate funds’ actual tracking difference side by side with my UCITS ETF comparison tool rather than relying on TER alone.
My verdict: which provider I would pick
If your priority is the lowest possible ongoing cost and you are accumulating monthly into one broad fund, Amundi Prime is the sharper tool. A world portfolio at roughly 0.07% is a genuine gift to European investors, and the Solactive indices track the same market reality as MSCI at a fraction of the licensing cost. Just go in with open eyes about Amundi’s habit of reorganising funds, and prefer the newer Irish-domiciled Prime funds where available.
If you want a fund you can buy once and ignore until retirement, I lean Xtrackers. The slightly higher TER buys you a stable ISIN, consistent domicile choices, and a line-up DWS clearly intends to leave alone. For swap-based US equity exposure it is the obvious pick, and for German investors running ETF savings plans, Xtrackers funds are ubiquitous and often carry zero execution fees at domestic brokers.
My own portfolio holds both, and neither choice is a mistake. Verify the current TER and domicile on the official Amundi ETF site or the Xtrackers site before you place the order, because these numbers move every year.
Often worth more than the TER gap: the free withholding tax and domicile calculator models fund-level US dividend withholding so you can compare like for like.
Frequently asked questions
Q: Is Amundi or Xtrackers cheaper for a world ETF?
A: On headline TER, Amundi wins. Its Prime All-Country World fund costs around 0.07% against roughly 0.12% to 0.19% for comparable Xtrackers world funds. The real-world gap can narrow once tracking difference and securities lending are counted, so compare the funds’ actual performance against their index, not just the fee line.
Q: Are Amundi and Xtrackers ETFs safe?
A: Yes, in the structural sense. Both issue UCITS funds where assets are segregated from the issuer and held by an independent depositary, so a failure of Amundi or DWS would not take your holdings down with it. The practical risks are ordinary market risk and, for synthetic funds, tightly collateralised swap counterparty risk.
Q: Why do Amundi funds keep changing ISINs and merging?
A: Amundi bought Lyxor in 2022 and inherited a large overlapping fund range, which it has been rationalising through mergers, index switches and domicile moves to Ireland. Each change can count as a taxable disposal in some countries, which is why long-term holders care. The pace has slowed as the integration completes, but the track record is worth knowing.
Q: Does Xtrackers still use synthetic replication?
A: Partly. Its flagship world, European and emerging markets equity funds are physically replicated, but DWS deliberately maintains swap-based funds where the structure adds return, most notably US equity exposure, where a synthetic UCITS fund avoids the 15% dividend withholding tax that physical Irish funds pay. Each factsheet states the replication method clearly.
Q: Which domicile is better, Luxembourg or Ireland?
A: For funds holding US shares, Ireland, because the US-Ireland tax treaty halves dividend withholding inside the fund from 30% to 15%. For European equity, bonds or synthetic US exposure, the difference largely disappears. Xtrackers already uses Ireland where it matters, and Amundi has been moving US-heavy funds there for the same reason.
Q: Can I just hold ETFs from both providers?
A: Absolutely, and I do. Issuer diversification costs you nothing and mildly reduces your exposure to any one company’s fund reorganisations. A common setup is a cheap Amundi Prime fund as the core accumulation vehicle plus an Xtrackers fund for a specific exposure, such as a swap-based S&P 500 or a single-country fund the others do not offer.
European UCITS/ETF investor with 11+ years building a global dividend and index portfolio, and founder of Financial Expert Class. I write every guide here from first-hand experience investing across EU brokers and tax regimes — not theory. More about me →